Global Glipizide (CAS 29094-61-9) Market Size By Type (Glipizide Tablets, Glipizide Sustained Release Tablets), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecast...

The Global Glipizide (CAS 29094-61-9) Market was valued at USD 1.12 billion in 2023 and is projected to reach USD 1.79 billion by 2031, expanding at a CAGR of 6.1% from 2023 to 2031. Glipizide, a second-generation sulfonylurea, is commonly prescribed for the treatment of type 2 diabetes mellitus due to its efficacy in lowering blood glucose levels. The market growth is fueled by rising diabetes prevalence globally, increasing geriatric population, and expanding access to essential diabetic therapies in emerging markets.

Drivers

Rising Prevalence of Type 2 Diabetes:

A major growth driver is the increasing global burden of type 2 diabetes, attributed to sedentary lifestyles, unhealthy diets, and aging populations. Glipizide remains a widely prescribed oral antidiabetic agent, particularly in regions with limited access to newer and costlier therapies.

Cost-Effectiveness Compared to Newer Drugs:

Glipizide offers a budget-friendly alternative to newer antidiabetic medications, making it a preferred choice in low- and middle-income countries, especially where healthcare reimbursement is constrained.

Increased Availability of Generic Versions:

With several pharmaceutical firms manufacturing glipizide generics, the drug is widely available globally, contributing to market penetration and adoption in both hospital and retail settings.

Restraints

Risk of Hypoglycemia and Cardiovascular Concerns:

As a sulfonylurea, glipizide carries a higher risk of hypoglycemia compared to newer drug classes like DPP-4 inhibitors or SGLT2 inhibitors. These side effects may deter healthcare providers from selecting glipizide as a first-line treatment.

Growing Preference for Newer Antidiabetic Medications:

Clinicians are increasingly shifting toward modern therapies with better safety profiles and additional cardiovascular benefits, thereby limiting the growth potential of glipizide in developed markets.

Opportunity

Untapped Markets in Africa and Southeast Asia:

These regions are witnessing a rapid increase in diabetes cases but often lack access to advanced treatments. The affordability and effectiveness of glipizide present an opportunity for pharmaceutical companies to expand their reach in these underpenetrated regions.

Combination Therapy Development:

The market can benefit from innovation in fixed-dose combinations of glipizide with metformin or other agents, improving patient adherence and expanding its clinical use.

Market by System Type Insights

By formulation type, the Immediate-Release Tablets segment held the dominant market share in 2023 due to its widespread use in initial glucose management. However, Extended-Release Tablets are expected to witness higher growth through 2031, driven by their once-daily dosing convenience and reduced side-effect profile.

Market by End-use Insights

The Hospital Pharmacies segment accounted for the largest market share in 2023, supported by high prescription rates and in-house diabetic care programs. The Retail Pharmacies segment is projected to grow rapidly as self-managed diabetes care and OTC purchases rise globally.

Market by Regional Insights

Asia-Pacific dominated the global Glipizide market in 2023, led by high diabetes prevalence, expanding healthcare access, and the popularity of generic medications in countries like China and India. North America holds a significant share due to its aging population, while Europe continues to maintain stable demand. The Middle East & Africa is expected to grow steadily, driven by healthcare infrastructure development.

Competitive Scenario

Leading players in the global Glipizide market include:

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Sun Pharmaceutical Industries Ltd.

Zydus Lifesciences Ltd.

Apotex Inc.

Aurobindo Pharma

Cipla Ltd.

Lupin Pharmaceuticals

Torrent Pharmaceuticals

Companies are focusing on expanding their manufacturing capacity, launching improved formulations, and targeting emerging markets through distribution partnerships.

Scope of Work – Global Glipizide (CAS 29094-61-9) Market

Key Market Developments

2023: Teva launched a new extended-release formulation of glipizide in the U.S., offering once-daily convenience.

2024: Cipla expanded its diabetic product portfolio by integrating glipizide into a combination therapy with metformin in select African markets.

2025: Zydus Lifesciences introduced a patient adherence program that includes subsidized glipizide therapy in Southeast Asia.

FAQs

1. What is the current market size of the Global Glipizide (CAS 29094-61-9) Market?

The market was valued at USD 1.12 billion in 2023.

2. What is the major growth driver of the Global Glipizide (CAS 29094-61-9) Market?

Rising global prevalence of type 2 diabetes and affordability of glipizide are key growth drivers.

3. Which is the largest region during the forecast period in the Global Glipizide (CAS 29094-61-9) Market?

Asia-Pacific dominates the market, driven by high diabetes rates and demand for generics.

4. Which segment accounted for the largest market share in Global Glipizide (CAS 29094-61-9) Market?

Immediate-release tablets accounted for the largest market share in 2023.

5. Who are the key market players in the Global Glipizide (CAS 29094-61-9) Market?

Major players include Pfizer, Teva, Mylan, Sun Pharma, Zydus, Cipla, and Lupin.